IMV Inc. Announces Second Quarter 2019 Financial Results and Provides Company Update Presented updated data from Phase 2 monotherapy arm of DeCidE1 study at ASCO 2019; DPX-Survivac exhibited durable ...

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company, announced today that it will hold a conference call and ...

IMV’s Phase 2 basket trial is an open label, multi-center study, evaluating DPX-Survivac across five cohorts of patients with bladder cancer, liver cancer (hepatocellular carcinoma), ovarian cancer, ...

Survivin-specific T cells remain active and proliferative over time, leading to T cell infiltration and the repopulation of up to 90% of the tumor microenvironment In connection with DeCidE1, IMV’s ...

ARLINGTON, Va., Sept. 15, 2019 /PRNewswire-PRWeb/ -- Today IMV, part of Science and Medicine Group and the leading market research and business intelligence provider to the medical imaging industry, ...

The American Society of Hematology has published the official abstracts on its meeting website in advance of the ASH Annual Meeting. The final conference poster presentation will include additional ...

One subject, who received three prior lines of systemic therapies and failed autologous stem cell transplant, reached a complete response at the first on-study scan following treatment with the ...

DARTMOUTH, Nova Scotia — IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, announced today that it ...

BEDFORD, Mass., Oct. 8, 2019 /PRNewswire/ -- Instrumentation Laboratory (IL) has been awarded Best System Performance in the Hemostasis category, as a part of the IMV ServiceTrak 2019 Clinical ...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today presented preliminary results from its ongoing Phase 2 basket trial, evaluating DPX-Survivac in combination with Merck ...